Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maha Hussain

Showing results (101-110 of 213) with videos related to

Pageof 22
Sort By:
The Journal of Urology|February 9, 2023
Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical TrialMaha Hussain, Cora N Sternberg, Eleni Efstathiou, et al.
Nutrition and Cancer|April 17, 2004
Soy isoflavones in the treatment of prostate cancerMaha Hussain, Mousumi Banerjee, Fazlul H Sarkar, et al.
European Journal of Cancer (Oxford, England : 1990)|June 18, 2015
A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancerMaha Hussain, Dana Rathkopf, Glenn Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2006
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)Maha Hussain, Catherine M Tangen, Celestia Higano, et al.
Cancers|December 10, 2021
The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical TrialsBertrand Tombal, Arnulf Stenzl, David Cella, et al.
Clinical Genitourinary Cancer|May 30, 2006
Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study designKathleen W Beekman, A Dimitrios Colevas, Kathleen Cooney, et al.
Cancer Research|April 11, 2022
A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate CancerYara Rodríguez, Kenji Unno, Mihai I Truica, et al.
Cancer|April 12, 2008
Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733Celestia S Higano, Catherine M Tangen, Wael A Sakr, et al.
The Prostate|November 7, 2017
Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancerHeather H Cheng, Melissa Plets, Hongli Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Living with prostate cancer: patients' and spouses' psychosocial status and quality of lifeLaurel L Northouse, Darlene W Mood, James E Montie, et al.
Pageof 22

Showing results (101-110 of 213) with videos related to

Sort By:
Pageof 22
The Journal of Urology|February 9, 2023
Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical TrialMaha Hussain, Cora N Sternberg, Eleni Efstathiou, et al.
Nutrition and Cancer|April 17, 2004
Soy isoflavones in the treatment of prostate cancerMaha Hussain, Mousumi Banerjee, Fazlul H Sarkar, et al.
European Journal of Cancer (Oxford, England : 1990)|June 18, 2015
A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancerMaha Hussain, Dana Rathkopf, Glenn Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2006
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)Maha Hussain, Catherine M Tangen, Celestia Higano, et al.
Cancers|December 10, 2021
The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical TrialsBertrand Tombal, Arnulf Stenzl, David Cella, et al.
Clinical Genitourinary Cancer|May 30, 2006
Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study designKathleen W Beekman, A Dimitrios Colevas, Kathleen Cooney, et al.
Cancer Research|April 11, 2022
A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate CancerYara Rodríguez, Kenji Unno, Mihai I Truica, et al.
Cancer|April 12, 2008
Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733Celestia S Higano, Catherine M Tangen, Wael A Sakr, et al.
The Prostate|November 7, 2017
Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancerHeather H Cheng, Melissa Plets, Hongli Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Living with prostate cancer: patients' and spouses' psychosocial status and quality of lifeLaurel L Northouse, Darlene W Mood, James E Montie, et al.
Pageof 22